Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
US11285134 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 28, 2024 |
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic